Continuous lenalidomide treatment for newly diagnosed multiple myeloma

Abstract

Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone-lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-lenalidomide (MPR) or melphalan-prednisone (MP)

Keywords

• multiple myeloma
• melphalan-prednisone-lenalidomide
• melphalan-prednisone
• randomized study